{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:15:22Z","timestamp":1774865722773,"version":"3.50.1"},"reference-count":40,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2003,7,1]]},"abstract":"<jats:p> Purpose: To study the response rates and duration of response after low-dose (4 Gy) involved field radiotherapy (LD-IF-RT) in patients with recurrent indolent lymphoma. <\/jats:p><jats:p> Patients and Methods: A total of 109 assessable patients (304 symptomatic sites) were irradiated (53 males and 56 females; median age, 62 years; range, 35 to 93), including 98 patients with follicular lymphoma (43 grade 1 and 55 grade 2), nine extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue-type and two patients with lymphoplasmacytoid lymphoma. Bulky disease (\u22655 cm) was present in 52% of all patients. A median of two prior regimens (range, 0 to 11) preceded LD-IF-RT. The median time since diagnosis was 41 months (range, 2 to 358 months). Time to (local) progression was calculated according to the Kaplan-Meier method. Differences in response rates between treatments within the same patient were compared using the McNemar test. <\/jats:p><jats:p> Results: The overall response rate was 92%; complete response was reached in 67 patients (61%), partial response in 34 patients (31%), stable disease in six patients (6%), and progressive disease in two patients (2%). The median time to progression was 14 months. The median time to local progression was 25 months. The 67 patients with complete response showed a median time to progression of 25 months and a median time to local progression of 42 months. None of the factors studied (age, sex, follicular lymphoma grade, radiotherapy regimen, number of previous regimens and previous history, number of positive sites or largest lymphoma diameter) were found to be related to response rate. <\/jats:p><jats:p> Conclusion: LD-IF-RT is a valuable asset in the management of patients with follicular lymphoma and should be considered in patients with recurrent disease. <\/jats:p>","DOI":"10.1200\/jco.2003.09.542","type":"journal-article","created":{"date-parts":[[2003,6,30]],"date-time":"2003-06-30T19:58:12Z","timestamp":1057003092000},"page":"2474-2480","source":"Crossref","is-referenced-by-count":153,"title":["High Response Rates and Lasting Remissions After Low-Dose Involved Field Radiotherapy in Indolent Lymphomas"],"prefix":"10.1200","volume":"21","author":[{"given":"R.L.M.","family":"Haas","sequence":"first","affiliation":[{"name":"From the Departments of Radiotherapy, Pathology, and Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; the Department of Radiotherapy, Bernard Verbeeten Institute, Tilburg, The Netherlands; the Department of Haematology, The Academic Medical Hospital, Amsterdam, The Netherlands., On behalf of the Haemato-Oncology Group of Amsterdam (HORA-Group)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ph.","family":"Poortmans","sequence":"additional","affiliation":[{"name":"From the Departments of Radiotherapy, Pathology, and Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; the Department of Radiotherapy, Bernard Verbeeten Institute, Tilburg, The Netherlands; the Department of Haematology, The Academic Medical Hospital, Amsterdam, The Netherlands., On behalf of the Haemato-Oncology Group of Amsterdam (HORA-Group)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"de Jong","sequence":"additional","affiliation":[{"name":"From the Departments of Radiotherapy, Pathology, and Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; the Department of Radiotherapy, Bernard Verbeeten Institute, Tilburg, The Netherlands; the Department of Haematology, The Academic Medical Hospital, Amsterdam, The Netherlands., On behalf of the Haemato-Oncology Group of Amsterdam (HORA-Group)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.M.P.","family":"Aleman","sequence":"additional","affiliation":[{"name":"From the Departments of Radiotherapy, Pathology, and Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; the Department of Radiotherapy, Bernard Verbeeten Institute, Tilburg, The Netherlands; the Department of Haematology, The Academic Medical Hospital, Amsterdam, The Netherlands., On behalf of the Haemato-Oncology Group of Amsterdam (HORA-Group)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.G.H.","family":"Dewit","sequence":"additional","affiliation":[{"name":"From the Departments of Radiotherapy, Pathology, and Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; the Department of Radiotherapy, Bernard Verbeeten Institute, Tilburg, The Netherlands; the Department of Haematology, The Academic Medical Hospital, Amsterdam, The Netherlands., On behalf of the Haemato-Oncology Group of Amsterdam (HORA-Group)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Verheij","sequence":"additional","affiliation":[{"name":"From the Departments of Radiotherapy, Pathology, and Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; the Department of Radiotherapy, Bernard Verbeeten Institute, Tilburg, The Netherlands; the Department of Haematology, The Academic Medical Hospital, Amsterdam, The Netherlands., On behalf of the Haemato-Oncology Group of Amsterdam (HORA-Group)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.M.","family":"Hart","sequence":"additional","affiliation":[{"name":"From the Departments of Radiotherapy, Pathology, and Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; the Department of Radiotherapy, Bernard Verbeeten Institute, Tilburg, The Netherlands; the Department of Haematology, The Academic Medical Hospital, Amsterdam, The Netherlands., On behalf of the Haemato-Oncology Group of Amsterdam (HORA-Group)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.H.J.","family":"van Oers","sequence":"additional","affiliation":[{"name":"From the Departments of Radiotherapy, Pathology, and Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; the Department of Radiotherapy, Bernard Verbeeten Institute, Tilburg, The Netherlands; the Department of Haematology, The Academic Medical Hospital, Amsterdam, The Netherlands., On behalf of the Haemato-Oncology Group of Amsterdam (HORA-Group)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"van der Hulst","sequence":"additional","affiliation":[{"name":"From the Departments of Radiotherapy, Pathology, and Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; the Department of Radiotherapy, Bernard Verbeeten Institute, Tilburg, The Netherlands; the Department of Haematology, The Academic Medical Hospital, Amsterdam, The Netherlands., On behalf of the Haemato-Oncology Group of Amsterdam (HORA-Group)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.W.","family":"Baars","sequence":"additional","affiliation":[{"name":"From the Departments of Radiotherapy, Pathology, and Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; the Department of Radiotherapy, Bernard Verbeeten Institute, Tilburg, The Netherlands; the Department of Haematology, The Academic Medical Hospital, Amsterdam, The Netherlands., On behalf of the Haemato-Oncology Group of Amsterdam (HORA-Group)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Bartelink","sequence":"additional","affiliation":[{"name":"From the Departments of Radiotherapy, Pathology, and Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; the Department of Radiotherapy, Bernard Verbeeten Institute, Tilburg, The Netherlands; the Department of Haematology, The Academic Medical Hospital, Amsterdam, The Netherlands., On behalf of the Haemato-Oncology Group of Amsterdam (HORA-Group)."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00401-8"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"R3","unstructured":"Portlock CS, Rosenberg SA, Glatstein E, et al: Management of low-grade non-Hodgkin\u2019s lymphomas. Semin Oncol 17:51,1990\u201359,"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/2.suppl_2.131"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/5.suppl_2.S67"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-4296(05)80025-6"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.4.881.881"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08039.x"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197603)37:3<1275::AID-CNCR2820370307>3.0.CO;2-M"},{"key":"R10","unstructured":"Bishop JF, Wiernik PH, Wesley MN, et al: A randomised trial of high dose cyclophosphamide, vincristine, and prednisone plus or minus doxorubicin (CVP versus CAVP) with long-term follow-up in advanced non-Hodgkin\u2019s lymphoma. Leukaemia 1:508,1987\u2013513,"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880201)61:3<441::AID-CNCR2820610306>3.0.CO;2-N"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309149108"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.41"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(91)90054-H"},{"key":"R15","unstructured":"Knospe WH, Loeb V Jr: Biweekly chlorambucil treatment of lymphocytic lymphoma. Cancer Clin Trials 3:329,1980\u2013336,"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199609000-00004"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1007\/BF00406577"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820915)50:6<1037::AID-CNCR2820500603>3.0.CO;2-N"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199308000-00008"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Lister TA, Cullen MH, Beard ME, et al: Comparison of combined and single-agent chemotherapy in non-Hodgkin\u2019s lymphoma of favourable histological type. BMJ 6112:533,1979\u2013537,","DOI":"10.1136\/bmj.1.6112.533"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(81)80185-7"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V47.5.747.bloodjournal475747"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-68-813-997"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-5107(96)00118-2"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90025-Y"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1282"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90272-6"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199008000-00002"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(87)90190-8"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-104-6-747"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(85)80086-4"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.6.1642.1642"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Girinsky T, Guillot-Vals D, Koscielny S, et al: A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys 51:148,2001\u2013155,","DOI":"10.1016\/S0360-3016(01)01626-1"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900120102"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(96)01854-3"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00358-0"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Johansson J, Specht L, Meijer J, et al: Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin\u2019s lymphoma (INHL) and chronic lymphocytic leukemia (CLL). Int J Radiat Oncol Biol Phys 51:361,2001\u2013362, (abstr)","DOI":"10.1016\/S0360-3016(01)02491-9"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.132253599"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2339"},{"key":"R40","unstructured":"Webster K, Cella D: Quality of life in patients with low-grade non-Hodgkin\u2019s lymphoma. Oncology 12:697,1998\u2013714,"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2003.09.542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:27:52Z","timestamp":1653510472000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2003.09.542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7,1]]},"references-count":40,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2003,7,1]]}},"alternative-id":["10.1200\/JCO.2003.09.542"],"URL":"https:\/\/doi.org\/10.1200\/jco.2003.09.542","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7,1]]}}}